Aligos Therapeutics (ALGS)
Develops liver- and viral-disease drug candidates, including a chronic hepatitis B program.
$6.00
vs last close+0.51 (+9.21%)
Something off on this page? Send us feedback.
Next report
Nov 5, 26
estimated · in 44 days
EPS estimate
−$2.44
Revenue estimate
$4.9M
Fiscal quarter
Q3 FY26
EPSReportedEstimate
Mar '25May '25Aug '25Nov '25Mar '26May '26Aug '26Nov '26
Reported−$13.08−$2.11−$1.53−$3.04−$1.91−$2.21−$0.14Pending
Estimate−$2.63−$2.80−$2.35−$2.09−$2.49−$2.29−$1.09−$2.44
Surprise−397.3%+24.6%+34.9%−45.5%+23.2%+3.5%+87.2%—
RevenueReportedEstimate
Mar '25May '25Aug '25Nov '25Mar '26May '26Aug '26Nov '26
Reported$629.0K$311.0K$965.0K$741.0K$169.0K$2.8M$27.8MPending
Estimate$433.3K$500.0K$433.3K$266.7K$440.0K$250.0K$24.7M$4.9M
Surprise+45.2%−37.8%+122.7%+177.9%−61.6%+1,032.0%+12.6%—
HistoryUpcoming
| Date / Period | Estimate | Reported | Surprise |
|---|---|---|---|
| Dec 2027 | −$1.06 | — | — |
| Sep 2027 | −$1.26 | — | — |
| Jun 2027 | −$1.66 | — | — |
| Mar 2027 | −$1.63 | — | — |
| Dec 2026 | −$1.87 | — | — |
| Nov 2026 | −$2.44 | — | — |
| Aug 2026 | −$1.09 | −$0.14 | +87.2% |
| May 2026 | −$2.29 | −$2.21 | +3.5% |
| Mar 2026 | −$2.49 | −$1.91 | +23.2% |
| Nov 2025 | −$2.09 | −$3.04 | −45.5% |
| Aug 2025 | |||
| May 2025 | |||
| Mar 2025 | |||
| Nov 2024 | |||
| Aug 2024 | |||
| May 2024 | |||
| Mar 2024 | |||
| Nov 2023 | |||
| Aug 2023 | |||
| May 2023 | |||
| Mar 2023 | |||
| Nov 2022 | |||
| Aug 2022 | |||
| May 2022 | |||
| Mar 2022 | |||
| Nov 2021 | |||
| Aug 2021 | |||
| May 2021 | |||
| Mar 2021 | |||
| Nov 2020 | |||
| Oct 2020 | |||
| Mar 2020 | |||
| Dec 2019 | |||
| Sep 2019 | |||
| Jun 2019 | |||
| Mar 2019 | |||
| Jun 2018 | |||
| Mar 2018 |
| Date / Period | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Reaction |
|---|---|---|---|---|---|---|---|
| Dec 2027 | −$1.06 | — | — | $4.4M | — | — | — |
| Sep 2027 | −$1.26 | — | — | $910.0K | — | — | — |
| Jun 2027 | −$1.66 | — | — | $220.0K | — | — | — |
| Mar 2027 | −$1.63 | — | — | $220.0K | — | — | — |
| Dec 2026 | −$1.87 | — | — | $537.5K | — | — | — |
| Nov 5, 2026 | −$2.44 | — | — | $4.9M | — | — | — |
| Aug 6, 2026 | −$1.09 | −$0.14 | +87.2% | $24.7M | $27.8M | +12.6% | +16.2% |
| May 7, 2026 | −$2.29 | −$2.21 | +3.5% | $250.0K | $2.8M | +1,032.0% | +6.8% |
| Mar 5, 2026 | −$2.49 | −$1.91 | +23.2% | $440.0K | $169.0K | −61.6% | −2.9% |
| Nov 6, 2025 | −$2.09 | −$3.04 | −45.5% | $266.7K | $741.0K | +177.9% | −3.1% |
| Aug 6, 2025 | |||||||
| May 6, 2025 | |||||||
| Mar 10, 2025 | |||||||
| Nov 6, 2024 | |||||||
| Aug 6, 2024 | |||||||
| May 7, 2024 | |||||||
| Mar 12, 2024 | |||||||
| Nov 2, 2023 | |||||||
| Aug 3, 2023 | |||||||
| May 4, 2023 | |||||||
| Mar 9, 2023 | |||||||
| Nov 2, 2022 | |||||||
| Aug 4, 2022 | |||||||
| May 4, 2022 | |||||||
| Mar 10, 2022 | |||||||
| Nov 4, 2021 | |||||||
| Aug 5, 2021 | |||||||
| May 10, 2021 | |||||||
| Mar 23, 2021 | |||||||
| Nov 25, 2020 | |||||||
| Oct 19, 2020 | |||||||
| Mar 31, 2020 | |||||||
| Dec 31, 2019 | |||||||
| Sep 30, 2019 | |||||||
| Jun 30, 2019 | |||||||
| Mar 31, 2019 | |||||||
| Jun 30, 2018 | |||||||
| Mar 31, 2018 |